Literature DB >> 16132114

Epigenetic activation of alpha4, beta2 and beta6 integrins involved in cell migration in trichostatin A-treated Hep3B cells.

Kuen-Tyng Lin1, Shiou-Hwei Yeh, Ding-Shinn Chen, Pei-Jer Chen, Yuh-Shan Jou.   

Abstract

The epigenetic modulation by histone deacetylase (HDAC) inhibitors including trichostatin A (TSA) has been known to block cell proliferation, induce apoptosis and inhibit cell migration in human cancer cells that represents the potential therapeutic agents for cancers and fibrosis. However, more than 55% of Hep3B cells remained alive after our initial study of 100 nM TSA treatment. To further study the epigenetic modulation and the biological function of newly activated genes by HDAC inhibitor involved in HCC progression and metastasis, we profiled 23 integrin genes including 15alpha and 8beta in TSA-treated Hep3B cells. Six integrins including three down-regulated alpha6, alpha10, beta8 and three significant up-regulated alpha4, beta2, beta6 integrins were revealed after semi-quantitative RT-PCR. To confirm the epigenetic modulation and explore their biological functions, we selected the three significantly up-regulated integrins for confirmation of protein up-regulation, hyperacetylated-histones by ChIP assays, and functional inhibition by specific neutralizing antibodies of integrins. Our results indicated that epigenetic modulation in TSA-treated Hep3B cells up-regulated new integrins including alpha4, beta2 and beta6 and reduced migration activities by specific neutralizing antibodies to 61.3%, 42.4% and 34.5%, respectively. Our novel findings provided a better understanding of the epigenetic modulation of integrins and suggested that targeting the epigenetic up-regulated integrins to abrogate the migration activity might be a promising strategy to prevent HCC progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132114     DOI: 10.1007/s11373-005-9005-2

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  7 in total

1.  Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast tumors.

Authors:  Luydmila A Mostovich; Tatiana Y Prudnikova; Aleksandr G Kondratov; Dina Loginova; Pavel V Vavilov; Valentina I Rykova; Sergei V Sidorov; Tatiana V Pavlova; Vladimir I Kashuba; Eugene R Zabarovsky; Elvira V Grigorieva
Journal:  Cell Adh Migr       Date:  2011 Sep-Oct       Impact factor: 3.405

Review 2.  Epigenetic regulation and targeting of ECM for cancer therapy.

Authors:  Romi Gupta
Journal:  Am J Physiol Cell Physiol       Date:  2022-03-02       Impact factor: 4.249

3.  Epigenetic contributions to cancer metastasis.

Authors:  David I Rodenhiser
Journal:  Clin Exp Metastasis       Date:  2008-04-02       Impact factor: 5.150

4.  N-terminal and C-terminal heparin-binding domain polypeptides derived from fibronectin reduce adhesion and invasion of liver cancer cells.

Authors:  Nan-Hong Tang; Yan-Lin Chen; Xiao-Qian Wang; Xiu-Jin Li; Yong Wu; Qi-Lian Zou; Yuan-Zhong Chen
Journal:  BMC Cancer       Date:  2010-10-13       Impact factor: 4.430

5.  Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration.

Authors:  Caterina Ierano; Agnes Basseville; Kenneth K W To; Zhirong Zhan; Robert W Robey; Julia Wilkerson; Susan E Bates; Stefania Scala
Journal:  Cancer Biol Ther       Date:  2012-11-28       Impact factor: 4.742

6.  The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.

Authors:  Norio Yamakawa; Kazuko Kaneda; Yusuke Saito; Emi Ichihara; Kazuhiro Morishita
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

7.  Transcriptomic and Epigenomic Profiling of Histone Deacetylase Inhibitor Treatment Reveals Distinct Gene Regulation Profiles Leading to Impaired Neutrophil Development.

Authors:  Anita M A P Govers; Caroline R M Wiggers; Ruben van Boxtel; Michal Mokry; Edward E S Nieuwenhuis; Menno P Creyghton; Marije Bartels; Paul J Coffer
Journal:  Hemasphere       Date:  2019-08-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.